US 9,808,484 B2
Anti-inflammatory composition for aiding and promoting the healing of chronic ulcerative lesions
Jorge Cueto Garcia, Col. Bosques de las Lomas C.P. (MX)
Assigned to Pebisut De Mexico S.A. DE C.V., Col. Lmas de Virreyes (MX)
Appl. No. 15/26,280
Filed by Pebisut De Mexico S.A. DE C.V., Col. Lmas de Virreyes, C.P. (MX)
PCT Filed Oct. 1, 2014, PCT No. PCT/MX2014/000152
§ 371(c)(1), (2) Date Mar. 31, 2016,
PCT Pub. No. WO2015/050425, PCT Pub. Date Apr. 9, 2015.
Claims priority of application No. MX/a/2013/011471 (MX), filed on Oct. 2, 2013.
Prior Publication US 2016/0243162 A1, Aug. 25, 2016
Int. Cl. A61K 33/30 (2006.01); A61K 31/718 (2006.01); A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 31/721 (2006.01); A61K 31/7016 (2006.01)
CPC A61K 33/30 (2013.01) [A61K 9/0014 (2013.01); A61K 9/10 (2013.01); A61K 31/7016 (2013.01); A61K 31/718 (2013.01); A61K 31/721 (2013.01)] 6 Claims
 
1. An anti-inflammatory and bacteriostatic composition comprising 53% by weight of non-hygroscopic maltodextrin, from 8 to 12% by weight of zinc oxide as thixotropy agent, 1.8% by weight of maltose, 0.0002% by weight of sodium, 0.0002% by weight of potassium, 0.0002% by weight of calcium, 0.0002% by weight of phosphorus, and 0.0006% by weight of magnesium, and the remainder water, wherein the anti-inflammatory and bacteriostatic composition has a viscosity greater than 100,000 cp and a pH from 5.6 to 6.9 for use in the treatment of chronic ulcerated lesions of diabetic foot and varicose ulcers.